Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1799 1
1806 1
1877 1
1988 1
1989 1
1991 1
1995 1
1996 3
1997 1
1998 2
1999 2
2000 1
2002 60
2003 54
2004 55
2005 56
2006 60
2007 61
2008 71
2009 84
2010 84
2011 74
2012 65
2013 86
2014 59
2015 49
2016 71
2017 69
2018 75
2019 65
2020 59
2021 22
Text availability
Article attribute
Article type
Publication date

Search Results

1,170 results
Results by year
Filters applied: . Clear all
Page 1
A Blueprint for Characterizing Senescence.
Roy AL, Sierra F, Howcroft K, Singer DS, Sharpless N, Hodes RJ, Wilder EL, Anderson JM. Roy AL, et al. Among authors: anderson jm. Cell. 2020 Nov 25;183(5):1143-1146. doi: 10.1016/j.cell.2020.10.032. Epub 2020 Oct 30. Cell. 2020. PMID: 33128870
Mutations, Cancer and the Telomere Length Paradox.
Aviv A, Anderson JJ, Shay JW. Aviv A, et al. Among authors: anderson jj. Trends Cancer. 2017 Apr;3(4):253-258. doi: 10.1016/j.trecan.2017.02.005. Epub 2017 Mar 27. Trends Cancer. 2017. PMID: 28718437 Free PMC article. Review.
Editorial - Withdrawal of Manuscript.
Anderson JM. Anderson JM. J Biomed Mater Res A. 2018 Oct;106(10):2581. doi: 10.1002/jbm.a.36542. J Biomed Mater Res A. 2018. PMID: 30354035 No abstract available.
Obesity: epigenetic aspects.
Kaushik P, Anderson JT. Kaushik P, et al. Among authors: anderson jt. Biomol Concepts. 2016 Jun 1;7(3):145-55. doi: 10.1515/bmc-2016-0010. Biomol Concepts. 2016. PMID: 27327133
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. Luke JJ, et al. Among authors: anderson jr. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. Future Oncol. 2020. PMID: 31870188 Free article.
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Robert C, et al. Among authors: anderson j. J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28. J Clin Oncol. 2018. PMID: 29283791 Clinical Trial.
Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Dix DB, et al. Among authors: anderson jr. J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi: 10.1200/JCO.2017.77.1931. Epub 2018 Apr 16. J Clin Oncol. 2018. PMID: 29659330 Free PMC article. Clinical Trial.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Long GV, et al. Among authors: anderson jr. Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17. Lancet Oncol. 2019. PMID: 31221619 Clinical Trial.
1,170 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page